• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Improving Care in Eosinophil-Associated Diseases: A Charter.改善嗜酸性粒细胞相关疾病的护理:宪章。
Adv Ther. 2022 Jun;39(6):2323-2341. doi: 10.1007/s12325-022-02110-8. Epub 2022 Apr 30.
2
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases.改善嗜酸性粒细胞相关疾病患者护理的原则的简明语言总结。
Immunotherapy. 2023 May 17. doi: 10.2217/imt-2022-0312.
3
Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities.生物疗法在罕见的嗜酸性粒细胞相关疾病中的应用:尚存问题与转化研究机遇。
J Leukoc Biol. 2024 Jul 25;116(2):307-320. doi: 10.1093/jleuko/qiae051.
4
Eosinophil-associated diseases: the Allergist's and Clinical Immunologist's perspective.嗜酸粒细胞相关疾病:过敏学家和临床免疫学家的视角。
Eur Ann Allergy Clin Immunol. 2024 Sep;56(5):195-209. doi: 10.23822/EurAnnACI.1764-1489.339. Epub 2024 Mar 28.
5
Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach.嗜酸粒细胞相关性炎症性疾病的管理:多学科方法的重要性。
Front Immunol. 2023 May 17;14:1192284. doi: 10.3389/fimmu.2023.1192284. eCollection 2023.
6
Cardiopulmonary and Gastrointestinal Manifestations of Eosinophil- associated Diseases and Idiopathic Hypereosinophilic Syndromes: Multimodality Imaging Approach.嗜酸性粒细胞相关疾病和特发性嗜酸性粒细胞增多综合征的心肺和胃肠道表现:多模态影像学方法。
Radiographics. 2016 Mar-Apr;36(2):433-51. doi: 10.1148/rg.2016150145.
7
Real-World Investigation of Eosinophilic-Associated Disease Overlap (REVEAL): Analysis of a US Claims Database.嗜酸性粒细胞相关疾病重叠的真实世界研究(REVEAL):美国索赔数据库分析
Allergy Asthma Immunol Res. 2023 Sep;15(5):580-602. doi: 10.4168/aair.2023.15.5.580.
8
Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD).重新审视 NIH 嗜酸性粒细胞相关疾病研究需求工作组(RE-TREAD)。
J Leukoc Biol. 2018 Jul;104(1):69-83. doi: 10.1002/JLB.5MR0118-028R. Epub 2018 Apr 19.
9
Global Quality Standard for Identification and Management of Severe Asthma.全球严重哮喘识别与管理质量标准。
Adv Ther. 2020 Sep;37(9):3645-3659. doi: 10.1007/s12325-020-01450-7. Epub 2020 Jul 28.
10
Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?嗜酸性粒细胞作为重度嗜酸性哮喘的驱动因素:表型还是可塑性?
Int J Mol Sci. 2021 Sep 21;22(18):10150. doi: 10.3390/ijms221810150.

引用本文的文献

1
Primary care physicians play a crucial role in diagnosing and managing rare eosinophilic diseases: HES and EGPA.基层医疗医生在诊断和管理罕见嗜酸性粒细胞疾病(高嗜酸性粒细胞综合征和嗜酸性肉芽肿性多血管炎)中发挥着关键作用。
Front Med (Lausanne). 2025 Jun 24;12:1568770. doi: 10.3389/fmed.2025.1568770. eCollection 2025.
2
High Disease Burden and Oral Corticosteroid Use in Patients with Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis: Country-Level Insights into Real-World Management in Europe.高嗜酸性粒细胞增多综合征和嗜酸性肉芽肿性多血管炎患者的高疾病负担及口服糖皮质激素使用情况:欧洲国家层面真实世界管理见解
J Clin Med. 2025 Jun 17;14(12):4309. doi: 10.3390/jcm14124309.
3
Optimizing diagnostic and management pathways for patients with eosinophilia of unknown origin: a multidisciplinary protocol for urgent and non-urgent evaluation.优化不明原因嗜酸性粒细胞增多症患者的诊断和管理路径:紧急和非紧急评估的多学科方案
Front Med (Lausanne). 2025 Jun 4;12:1544047. doi: 10.3389/fmed.2025.1544047. eCollection 2025.
4
Tracking Public Interest in Rare Diseases and Eosinophilic Disorders in Germany: Web Search Analysis.追踪德国公众对罕见病和嗜酸性粒细胞疾病的关注:网络搜索分析
JMIR Infodemiology. 2025 May 26;5:e69040. doi: 10.2196/69040.
5
Disease Overlap, Healthcare Resource Utilization, and Costs in Patients with Eosinophilic Granulomatosis with Polyangiitis: A REVEAL Sub-study.嗜酸性肉芽肿性多血管炎患者的疾病重叠、医疗资源利用及成本:一项REVEAL子研究
Rheumatol Ther. 2024 Dec;11(6):1611-1628. doi: 10.1007/s40744-024-00714-w. Epub 2024 Oct 24.
6
Duodenal stenosis, an unusual presentation of eosinophilic gastroenteritis: a case report.十二指肠狭窄——嗜酸性粒细胞性胃肠炎的一种罕见表现:病例报告
Front Pediatr. 2024 Apr 18;12:1390946. doi: 10.3389/fped.2024.1390946. eCollection 2024.
7
Challenges in Diagnosis and Management of Unusual Cases of Eosinophilic Enteritis in Rural Health Settings: A Comprehensive Review.农村卫生环境中嗜酸性粒细胞性肠炎罕见病例的诊断与管理挑战:一项综合综述
Cureus. 2024 Mar 2;16(3):e55398. doi: 10.7759/cureus.55398. eCollection 2024 Mar.
8
Descriptive Analysis of Pre-existing Data on Eosinophilic Esophagitis and Associated Morbidities in Cleveland Clinic Abu Dhabi, United Arab Emirates.阿联酋阿布扎比克利夫兰诊所嗜酸性食管炎及相关疾病既往数据的描述性分析。
Cureus. 2024 Jan 1;16(1):e51493. doi: 10.7759/cureus.51493. eCollection 2024 Jan.
9
Eosinophilic-Associated Disease Overlap: What Do We Know About It?嗜酸性粒细胞相关疾病重叠:我们对此了解多少?
Allergy Asthma Immunol Res. 2023 Sep;15(5):539-542. doi: 10.4168/aair.2023.15.5.539.
10
Addressing educational gaps through multidisciplinary team education in eosinophilic oesophagitis management.通过嗜酸性粒细胞性食管炎管理的多学科团队教育来解决教育差距。
J CME. 2023 Jul 6;12(1):2230033. doi: 10.1080/28338073.2023.2230033. eCollection 2023.

本文引用的文献

1
The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom.英国嗜酸性粒细胞增多综合征发病率和患病率的上升。
Immun Inflamm Dis. 2021 Dec;9(4):1447-1451. doi: 10.1002/iid3.495. Epub 2021 Jul 22.
2
Multidisciplinary Eosinophilic Esophagitis Care: A Model for Comprehensive Patient-Centered Care Through Shared Decision Making Between Gastroenterology, Allergy, and Nutrition.多学科嗜酸性食管炎护理:一种通过胃肠病学、过敏和营养之间的共同决策实现以患者为中心的全面护理模式。
Clin Gastroenterol Hepatol. 2021 Nov;19(11):2226-2229. doi: 10.1016/j.cgh.2021.07.025. Epub 2021 Jul 16.
3
Defining a Severe Asthma Super-Responder: Findings from a Delphi Process.定义重度哮喘超高反应者:德尔菲法研究结果。
J Allergy Clin Immunol Pract. 2021 Nov;9(11):3997-4004. doi: 10.1016/j.jaip.2021.06.041. Epub 2021 Jul 13.
4
Emerging Evidence for Pleiotropism of Eosinophils.嗜酸性粒细胞的多效性的新证据。
Int J Mol Sci. 2021 Jun 30;22(13):7075. doi: 10.3390/ijms22137075.
5
Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.在美国管理式医疗数据库中评估嗜酸性肉芽肿性多血管炎的疾病负担和相关成本。
J Manag Care Spec Pharm. 2021 Sep;27(9):1249-1259. doi: 10.18553/jmcp.2021.21002. Epub 2021 Jun 24.
6
Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis.与嗜酸性肉芽肿性多血管炎相关的疾病负担:系统文献回顾和荟萃分析。
Clin Rheumatol. 2021 Dec;40(12):4829-4836. doi: 10.1007/s10067-021-05783-8. Epub 2021 Jun 23.
7
Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort.嗜酸粒细胞性和非嗜酸粒细胞性哮喘:全球真实严重哮喘队列中表型特征的专家共识框架。
Chest. 2021 Sep;160(3):814-830. doi: 10.1016/j.chest.2021.04.013. Epub 2021 Apr 19.
8
Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.嗜酸性粒细胞敲除人类:通过靶向嗜酸性粒细胞的生物治疗揭示嗜酸性粒细胞的作用。
Annu Rev Immunol. 2021 Apr 26;39:719-757. doi: 10.1146/annurev-immunol-093019-125918. Epub 2021 Mar 1.
9
Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study.嗜酸细胞性胃炎和(或)十二指肠炎患者的诊断延迟:一项基于人群的研究。
J Allergy Clin Immunol Pract. 2021 May;9(5):2050-2059.e20. doi: 10.1016/j.jaip.2020.12.054. Epub 2021 Jan 10.
10
Potential Severe Asthma Hidden in UK Primary Care.英国初级保健中潜在的严重哮喘。
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1612-1623.e9. doi: 10.1016/j.jaip.2020.11.053. Epub 2020 Dec 9.

改善嗜酸性粒细胞相关疾病的护理:宪章。

Improving Care in Eosinophil-Associated Diseases: A Charter.

机构信息

Guy's Severe Asthma Centre, Guy's Hospital, Guy's and St Thomas' NHS Trust, School of Immunology and Microbial Sciences, King's College London, London, SE1 9RT, UK.

School of Immunology and Microbial Sciences, King's College, London, UK.

出版信息

Adv Ther. 2022 Jun;39(6):2323-2341. doi: 10.1007/s12325-022-02110-8. Epub 2022 Apr 30.

DOI:10.1007/s12325-022-02110-8
PMID:35489014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9055373/
Abstract

Eosinophil-associated diseases (EADs) are a range of heterogeneous conditions in which eosinophils are believed to play a critical pathological role. EADs include common illnesses such as eosinophilic asthma and chronic rhinosinusitis and rare conditions such as hypereosinophilic syndromes (HES) and eosinophilic gastrointestinal disorders (EGIDs). EADs are associated with substantial burdens for the patient, including chronic, debilitating symptoms, increased financial burden, decreased health-related quality of life, and the need for repeated visits to multiple different healthcare professionals (HCPs), emergency departments, and/or hospitals. Poor EAD recognition by HCPs often contributes to delayed diagnoses, which further delays patient access to appropriate care and effective treatments, contributing to poor health outcomes. The objective of this charter is to outline key patient rights and expectations with respect to the management of their condition(s) and to set forth an ambitious action plan to improve health outcomes for patients with EADs: (1) people with EADs, their caretakers, HCPs, and the public must have greater awareness and education about EADs; (2) people with EADs must receive a timely, accurate diagnosis; (3) all people with EADs must have access to an appropriate multidisciplinary team, when necessary; and (4) people with EADs must have access to safe and effective treatment options without unnecessary regulatory delays. The principles described in this charter demonstrate the core elements of quality care that people with EADs must receive, and they represent clear steps by which to reduce patient and caregiver burden and improve patient outcomes. We urge HCPs, healthcare systems, and policymakers worldwide to swiftly adopt these principles to ensure patients with EADs have an accurate diagnosis in a timely manner and access to high-level care and treatment in an appropriate setting.

摘要

嗜酸粒细胞相关疾病(EADs)是一系列异质性疾病,其中嗜酸粒细胞被认为在病理上发挥关键作用。EADs 包括常见疾病,如嗜酸粒细胞性哮喘和慢性鼻-鼻窦炎,以及罕见疾病,如嗜酸性粒细胞增多综合征(HES)和嗜酸粒细胞性胃肠病(EGIDs)。EADs 给患者带来了巨大的负担,包括慢性、衰弱性症状、增加的经济负担、降低的健康相关生活质量,以及需要多次就诊于多个不同的医疗保健专业人员(HCPs)、急诊部门和/或医院。HCPs 对 EAD 的识别不足常常导致诊断延迟,这进一步延迟了患者获得适当治疗的机会,导致健康结果不佳。本宪章的目的是概述患者在管理其病情方面的关键权利和期望,并制定一项雄心勃勃的行动计划,以改善 EAD 患者的健康结果:(1)EAD 患者、其照顾者、HCPs 和公众必须对 EAD 有更多的认识和教育;(2)EAD 患者必须及时、准确地诊断;(3)所有 EAD 患者都必须在必要时获得适当的多学科团队;以及(4)EAD 患者必须能够获得安全有效的治疗方案,而不会因不必要的监管延迟而受到影响。本宪章中描述的原则展示了 EAD 患者必须获得的优质护理的核心要素,它们代表了减少患者和护理者负担并改善患者结局的明确步骤。我们敦促全球的 HCPs、医疗保健系统和政策制定者迅速采纳这些原则,以确保 EAD 患者能够及时获得准确的诊断,并在适当的环境中获得高水平的护理和治疗。